NovaBridge Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 13, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	370	69	158	347	3,647	3,324
Market Cap Growth	328.73%	-56.10%	-54.60%	-90.48%	9.73%	-
Enterprise Value	145	-134	-238	-223	2,916	3,115
Last Close Price	3.21	0.85	1.90	4.18	47.39	47.15
PE Ratio	-	-	-	-	-	46.08
Forward PE	-	-	-	-	-	85.14
PS Ratio	-	-	249.50	-223.95	263.21	14.07
PB Ratio	1.43	0.34	0.65	0.82	5.08	3.86
P/TBV Ratio	1.43	0.34	0.65	0.91	5.42	4.06
P/FCF Ratio	-	-	-	-	-	50.99
P/OCF Ratio	-	-	-	-	-	50.05
EV/Sales Ratio	-	-	-	-	210.43	13.18
EV/EBITDA Ratio	-	-	-	-	-	120.82
EV/EBIT Ratio	-	-	-	-	-	130.71
EV/FCF Ratio	-	-	-	-	-	47.79
Debt / Equity Ratio	0.01	0.02	0.02	0.03	0.03	0.00
Debt / EBITDA Ratio	-	-	-	-	-	0.08
Debt / FCF Ratio	-	-	-	-	-	0.03
Net Debt / Equity Ratio	-0.87	-0.84	-1.27	-1.16	-0.91	-0.85
Net Debt / EBITDA Ratio	6.49	3.31	6.35	9.27	2.02	-28.38
Net Debt / FCF Ratio	13.24	1.59	2.10	5.31	4.15	-11.22
Asset Turnover	-	-	0.00	-	0.02	0.38
Quick Ratio	14.24	20.65	5.39	4.60	7.48	9.12
Current Ratio	14.47	20.90	5.67	4.78	7.66	9.28
Return on Equity (ROE)	-	-22.40%	-24.75%	-26.08%	-45.78%	14.06%
Return on Assets (ROA)	-	-11.05%	-6.38%	-4.73%	-21.69%	2.41%
Return on Invested Capital (ROIC)	-101.41%	-	-	-	-338.80%	34.43%
Return on Capital Employed (ROCE)	-13.30%	-25.20%	-15.80%	-11.00%	-41.60%	2.70%
Earnings Yield	-7.11%	-32.12%	-131.74%	-106.82%	-10.06%	2.17%
FCF Yield	-4.59%	-154.11%	-93.01%	-26.58%	-4.33%	1.96%
Buyback Yield / Dilution	-6.88%	2.45%	-0.86%	-8.63%	-11.11%	-2030.15%

Updated Oct 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q